These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11942571)

  • 1. P-cadherin expression is associated with high-grade ductal carcinoma in situ of the breast.
    Paredes J; Milanezi F; Viegas L; Amendoeira I; Schmitt F
    Virchows Arch; 2002 Jan; 440(1):16-21. PubMed ID: 11942571
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Carcinomas in situ of the breast with indeterminate features: role of E-cadherin staining in categorization.
    Jacobs TW; Pliss N; Kouria G; Schnitt SJ
    Am J Surg Pathol; 2001 Feb; 25(2):229-36. PubMed ID: 11176072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Solid low-grade in situ carcinoma of the breast: role of associated lesions and E-cadherin in differential diagnosis.
    Maluf HM; Swanson PE; Koerner FC
    Am J Surg Pathol; 2001 Feb; 25(2):237-44. PubMed ID: 11176073
    [TBL] [Abstract][Full Text] [Related]  

  • 4. E-cadherin (E-cad) expression in duct carcinoma in situ (DCIS) of the breast.
    Gupta SK; Douglas-Jones AG; Jasani B; Morgan JM; Pignatelli M; Mansel RE
    Virchows Arch; 1997 Jan; 430(1):23-8. PubMed ID: 9037311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression of P-cadherin, but not E-cadherin or N-cadherin, relates to pathological and functional differentiation of breast carcinomas.
    Kovács A; Dhillon J; Walker RA
    Mol Pathol; 2003 Dec; 56(6):318-22. PubMed ID: 14645693
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The biological and prognostic significance of cell polarity and E-cadherin in grade I infiltrating ductal carcinoma of the breast.
    Tan DS; Potts HW; Leong AC; Gillett CE; Skilton D; Harris WH; Liebmann RD; Hanby AM
    J Pathol; 1999 Sep; 189(1):20-7. PubMed ID: 10451483
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P-cadherin and cytokeratin 5: useful adjunct markers to distinguish basal-like ductal carcinomas in situ.
    Paredes J; Lopes N; Milanezi F; Schmitt FC
    Virchows Arch; 2007 Jan; 450(1):73-80. PubMed ID: 17123107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic markers in ductal carcinoma in situ and concurrent infiltrating carcinoma. A comparison of eight contemporary grading systems.
    Leong AS; Sormunen RT; Vinyuvat S; Hamdani RW; Suthipintawong C
    Am J Clin Pathol; 2001 May; 115(5):709-18. PubMed ID: 11345835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correlation between type and grade of ductal carcinoma in situ and concomitant invasive ductal carcinoma of the breast.
    Rudnicka L; Stachura J
    Pol J Pathol; 2000; 51(3):137-43. PubMed ID: 11247396
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Expression of Twist, E-cadherin and N-cadherin in breast carcinoma and their clinical significance].
    Ma YH; Wang K; Li L; Lu ZH; Chen J
    Zhonghua Bing Li Xue Za Zhi; 2010 Jan; 39(1):5-9. PubMed ID: 20388391
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An evaluation of ductal carcinoma in-situ of breast and its correlation with the grade of associated invasive component.
    Konar K; Chatterjee U; Dutta SK
    Indian J Pathol Microbiol; 2001 Jul; 44(3):297-300. PubMed ID: 12024916
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Usefulness and limitations of E-cadherin and β-catenin in the classification of breast carcinomas in situ with mixed pattern.
    Gomes DS; Porto SS; Rocha RM; Gobbi H
    Diagn Pathol; 2013 Jul; 8():114. PubMed ID: 23837653
    [TBL] [Abstract][Full Text] [Related]  

  • 13. E-cadherin expression correlates with histologic type but not tumour grade in invasive breast cancer.
    Nurismah MI; Noriah O; Suryati MY; Sharifah NA
    Asian Pac J Cancer Prev; 2008; 9(4):699-702. PubMed ID: 19256762
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunoreactive p53 and metallothionein expression in duct carcinoma in situ of the breast. No correlation.
    Douglas-Jones AG; Navabi H; Morgan JM; Jasani B
    Virchows Arch; 1997 May; 430(5):373-9. PubMed ID: 9174627
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Immunohistochemical study of P-cadherin in breast cancer].
    Kovács A; Walker RA; Nagy A; Gomba S; Jones L; Dearing S
    Orv Hetil; 2002 Feb; 143(8):405-9. PubMed ID: 11921707
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The clinical behavior of breast carcinoma is probably determined at the preinvasive stage (ductal carcinoma in situ).
    Gupta SK; Douglas-Jones AG; Fenn N; Morgan JM; Mansel RE
    Cancer; 1997 Nov; 80(9):1740-5. PubMed ID: 9351542
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of E-cadherin catenin and C-erbB-2 gene products in invasive ductal-type breast carcinomas.
    Nagae Y; Kameyama K; Yokoyama M; Naito Z; Yamada N; Maeda S; Asano G; Sugisaki Y; Tanaka S
    J Nippon Med Sch; 2002 Apr; 69(2):165-71. PubMed ID: 12068329
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative/low HER2 expression alone or combined with E-cadherin positivity is predictive of better prognosis in patients with breast carcinoma.
    Karray-Chouayekh S; Trifa F; Khabir A; Sellami-Boudawara T; Frikha M; Gargouri A; Mokdad-Gargouri R
    Histol Histopathol; 2012 Mar; 27(3):377-85. PubMed ID: 22237715
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Differential loss of E-cadherin expression in infiltrating ductal and lobular breast carcinomas.
    Moll R; Mitze M; Frixen UH; Birchmeier W
    Am J Pathol; 1993 Dec; 143(6):1731-42. PubMed ID: 8256859
    [TBL] [Abstract][Full Text] [Related]  

  • 20. P-cadherin expression in breast carcinoma indicates poor survival.
    Peralta Soler A; Knudsen KA; Salazar H; Han AC; Keshgegian AA
    Cancer; 1999 Oct; 86(7):1263-72. PubMed ID: 10506713
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.